KEGG   DRUG: Ciltacabtagene autoleucel
Entry
D12315                      Drug                                   
Name
Ciltacabtagene autoleucel (USAN/INN);
Carvykti (TN);
Carvykti (TN)
Product
CARVYKTI (Janssen Biotech)
Remark
ATC code: L01XL05
Product: D12315<US>
Efficacy
Antineoplastic
  Disease
Multiple myeloma [DS:H00010]
  Type
Cellular therapy product, CAR-T cell therapy
Comment
Treatment of multiple myeloma
Target
TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
CD38 [HSA:952] [KO:K01242]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04640  Hematopoietic cell lineage
hsa04672  Intestinal immune network for IgA production
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL05 Ciltacabtagene autoleucel
      D12315  Ciltacabtagene autoleucel (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Tumor necrosis factor receptors
    TNFRSF17 (BCMA, CD269)
     D12315  Ciltacabtagene autoleucel (USAN/INN) <US>
 Enzymes
  Hydrolases (EC3)
   ADP-ribosyl cyclase
    CD38
     D12315  Ciltacabtagene autoleucel (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12315
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12315
New drug approvals in Japan [br08318.html]
 Cellular and gene therapy products
  D12315
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12315
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system